CytoDyn Inc. (CYDY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CytoDyn Inc. (CYDY) Healthcare & Pipeline Overview

CytoDyn Inc. is a clinical-stage biotechnology firm specializing in the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Its focus areas include COVID-19, oncology (metastatic triple-negative breast cancer and micro-satellite stable colorectal cancer), and collaborations like the one with Creatv Bio, positioning it within the competitive biotechnology sector.

What Is the Investment Thesis for CYDY?

CytoDyn Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is largely dependent on the successful clinical development and regulatory approval of leronlimab. Key value drivers include positive Phase 2 trial results for its oncology programs and potential partnerships for commercialization. The company's beta of 1.27 indicates higher volatility compared to the market. A significant risk factor is the company's reliance on a single drug candidate and the inherent uncertainty of clinical trials. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the company's progress. As of 2026-03-16, the company's market capitalization is $272M, reflecting investor sentiment and expectations regarding future success.

Based on FMP financials and quantitative analysis

CYDY Key Highlights

CytoDyn Inc. is focused on the clinical development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor.

• Leronlimab is currently in Phase 2 clinical development for micro-satellite stable colorectal cancer and solid tumors, including metastatic triple-negative breast cancer.
• The company has a collaboration with Creatv Bio to advance its research and development efforts.
• CytoDyn's market capitalization is $272M as of 2026-03-16, reflecting investor sentiment.
• The company's beta of 1.27 indicates higher volatility compared to the market.

Who Are CYDY's Competitors?

CYDY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CYDY's Key Strengths?

Novel therapeutic approach targeting the CCR5 receptor.

• Potential applications in multiple therapeutic areas.
• Collaboration with Creatv Bio.

What Are CYDY's Weaknesses?

Reliance on a single drug candidate.

• Limited financial resources.
• High risk of clinical trial failure.

What Could Drive CYDY Stock Higher?

Phase 2 clinical trial results for micro-satellite stable colorectal cancer (timeline unknown).

• Phase 2 clinical trial results for metastatic triple-negative breast cancer (timeline unknown).
• Potential for new partnerships and collaborations.
• Regulatory updates regarding leronlimab's development.

What Are the Key Risks for CYDY?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Clinical trial failures for leronlimab.
• Regulatory delays or rejection of leronlimab.
• Competition from established pharmaceutical companies.
• Limited financial resources and dependence on external funding.
• Patent expiration and intellectual property challenges.

What Are the Growth Opportunities for CYDY?

• Expansion into New Oncology Indications: CytoDyn has the opportunity to expand the application of leronlimab into additional oncology indications beyond micro-satellite stable colorectal cancer and metastatic triple-negative breast cancer. This could involve targeting other solid tumors or hematological malignancies. The oncology drug market is projected to reach $250 billion by 2030, offering a substantial market opportunity for successful therapies. This expansion would require further clinical trials and regulatory approvals, with a potential timeline of 3-5 years.
• Partnerships and Collaborations: CytoDyn can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of leronlimab. These partnerships could provide access to additional funding, expertise, and distribution channels. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation, with deal values reaching billions of dollars annually. A successful partnership could significantly enhance CytoDyn's market position and financial resources, with potential deals materializing within the next 1-2 years.
• Advancement of COVID-19 Program: Although the COVID-19 pandemic has subsided, CytoDyn could explore potential applications of leronlimab in treating long-term COVID-19 symptoms or other viral infections. The long-COVID market is still emerging, but some analysts estimate it could reach billions of dollars in the coming years. This would require additional clinical trials and regulatory approvals, with a potential timeline of 2-4 years.
• Geographic Expansion: CytoDyn can expand its clinical trials and commercialization efforts into new geographic regions, particularly in Asia and Europe, where there is a growing demand for innovative cancer therapies. The global oncology market is expanding rapidly, with emerging markets offering significant growth opportunities. This expansion would require regulatory approvals and partnerships with local distributors, with a potential timeline of 3-5 years.
• Leveraging Orphan Drug Designation: CytoDyn can seek orphan drug designation for leronlimab in specific rare cancer subtypes. Orphan drug designation provides several benefits, including market exclusivity and tax incentives, which can enhance the commercial viability of the drug. The orphan drug market is growing faster than the overall pharmaceutical market, driven by unmet medical needs and regulatory support. This designation could be pursued within the next 1-2 years, depending on the specific cancer subtype targeted.

What Are CYDY's Competitive Advantages?

• Patent protection for leronlimab (limited information available).
• Clinical data supporting the efficacy of leronlimab (limited information available).
• Strategic collaborations with research institutions and other companies.

What Does CYDY Do?

CytoDyn Inc., formerly RexRay Corporation, was founded in 2002 and is headquartered in Vancouver, Washington. It operates as a clinical-stage biotechnology company dedicated to developing innovative treatments for a range of therapeutic indications. The company's primary focus is on the clinical development of leronlimab, a humanized monoclonal antibody that targets the C-C chemokine receptor type 5 (CCR5). Leronlimab is being investigated for its potential in treating COVID-19, micro-satellite stable colorectal cancer, and solid tumors, including metastatic triple-negative breast cancer. CytoDyn's approach involves strategic collaborations, such as its partnership with Creatv Bio, to advance its research and development efforts. The company is currently in Phase 2 clinical development for several of its oncology programs. CytoDyn aims to address unmet medical needs through its targeted therapies, navigating the complex regulatory landscape to bring its products to market.

What Products and Services Does CYDY Offer?

• Develops leronlimab, a humanized monoclonal antibody.
• Targets the CCR5 receptor for therapeutic intervention.
• Conducts clinical trials for COVID-19 treatment.
• Investigates leronlimab for micro-satellite stable colorectal cancer.
• Explores leronlimab's potential in treating metastatic triple-negative breast cancer.
• Collaborates with Creatv Bio for research and development.

How Does CYDY Make Money?

• Focuses on developing and commercializing leronlimab.
• Generates revenue through potential future sales of leronlimab.
• Relies on partnerships and collaborations for funding and expertise.

What Industry Does CYDY Operate In?

CytoDyn Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for oncology drugs is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like CytoDyn are striving to develop novel therapies that address unmet medical needs. The success of biotechnology companies depends on their ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy. The biotechnology industry is subject to rapid technological advancements and evolving scientific understanding, requiring companies to remain innovative and adaptable.

Who Are CYDY's Key Customers?

• Patients with COVID-19 (potential future market).
• Patients with micro-satellite stable colorectal cancer (clinical trial participants).
• Patients with metastatic triple-negative breast cancer (clinical trial participants).

CytoDyn Inc. (CYDY) Valuation Context

Valued at $272M, CYDY is classified as a micro-cap stock. Relative to its peer group, CYDY's quantitative score of 47/100 is below the peer average of 78/100.

CYDY Revenue & Earnings Trend

In Q4 FY2026, CYDY generated $0 in top-line revenue. The company recorded a net loss of $9.9M, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CYDY averaged $-0.01 in diluted EPS.

Company Profile

CytoDyn Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, US. The company is led by CEO Jacob Lalezari. CYDY has traded publicly since 2006.

Return on equity for CytoDyn Inc. stands at 37.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -5.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.37 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -12.7%, the inverse of the P/E and a quick read on earnings relative to price.

CytoDyn Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

CytoDyn Inc. has beaten Wall Street's EPS estimate in 3 of its last 3 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 85.7% above estimates on average.

Over the past six months, CytoDyn Inc. insiders filed 8 SEC Form 4 transactions — 0 sales and 8 purchases. On net that is roughly 15.9M shares acquired (about $4.4M) — insiders putting money in tends to read as conviction.

CYDY Financials

CYDY Latest News

CYDY Analyst Consensus

CYDY MoonshotScore

CytoDyn Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources